R1 Therapeutics Expands Series A to $80.5M

R1 Therapeutics has expanded its Series A financing from $77.5M to $80.5M as Samsara BioCapital joins the investor syndicate. The September 30, 2026 announcement adds capital while the company's lead program, AP306, is already being evaluated in a global Phase 2b trial for hyperphosphatemia in adults receiving maintenance hemodialysis.

The timing matters more than the $3M increase. R1 has moved past assembling a company around an interesting mechanism and into the expensive work of producing a blinded clinical readout. Topline data from the approximately 168-participant study are expected in the first half of 2027, making this financing an investment in evidence generation rather than a reset of the company's scientific argument.

What Changed in R1 Therapeutics' Series A

R1 Therapeutics launched publicly in March 2026 with an oversubscribed $77.5M Series A co-led by Abingworth, DaVita Venture Group and F-Prime. Curie.Bio, SNMA Capital, previously known as SymBiosis Capital Management, and U.S. Renal Care also participated. The latest announcement brings Samsara BioCapital into that group and raises the Series A total to $80.5M.

R1 did not disclose its valuation or separately identify Samsara's check size. The difference between the two announced totals is $3M, so the clean capital accounting is an expansion from $77.5M to $80.5M, not a new $80.5M raise. R1 says the proceeds will support continued development of AP306 through its global Phase 2b program.

The syndicate combines specialist life-sciences investors with kidney-care operators. DaVita and U.S. Renal Care bring direct exposure to the dialysis environment AP306 is designed to serve, while Samsara describes itself as a therapeutics investor working across private and public markets. Their participation supports R1's ability to run the program, but it is not evidence that the medicine will succeed.

Why Hyperphosphatemia Remains Difficult in Dialysis Care

Healthy kidneys help regulate phosphate. In advanced chronic kidney disease, that control can break down, leaving elevated phosphate levels associated with bone disease, cardiovascular complications and mortality. R1 cites U.S. Renal Data System evidence to say more than 70% of U.S. dialysis patients fail to reach normal phosphate levels, despite phosphate binders having served as standard therapy for decades.

The practical burden matters alongside the laboratory value. Existing approaches often require patients to coordinate multiple pills with meals while already managing the demands of maintenance dialysis. R1 is developing AP306 as an investigational monotherapy that acts locally in the gastrointestinal tract and inhibits active phosphate transport through NaPi-IIb, PiT-1 and PiT-2.

That mechanism distinguishes AP306 from therapies centered on binding phosphate and reducing passive absorption. It does not yet establish a better clinical outcome. Published Phase 2a research reported significant reductions in serum phosphate with favorable safety and tolerability, giving R1 a clinical basis for the next study while leaving the larger efficacy and dose-selection questions open.

The Phase 2b Study Now Carries the Story

The Phase 2b study, NCT06712654, is randomized, double-blind, placebo-controlled and multicenter. R1 and Alebund Pharmaceuticals plan to enroll approximately 168 adults receiving maintenance hemodialysis at sites in the United States and China. Participants are assigned across six fixed-dose AP306 regimens and placebo for eight weeks.

The primary endpoint is the change in serum phosphate from baseline to the end of treatment. Secondary measures include the proportion of participants reaching the target phosphate range and the time required to achieve phosphate control. Those design choices should help R1 understand both whether AP306 lowers phosphate and which dose pattern could support a Phase 3 program.

AP306 was originally discovered by Chugai Pharmaceutical and subsequently licensed to Alebund in 2021. R1 obtained exclusive development and commercialization rights outside Greater China as part of its launch, while Alebund remains the partner for the global program. The arrangement gives the young company a clinical-stage asset and shared international development infrastructure, but also concentrates most of its visible value in one program.

Leadership Built for a Clinical Handoff

Krishna Polu, M.D., R1's co-founder, president and CEO, is a nephrologist with more than 20 years of biopharmaceutical development experience. L. Mary Smith, Ph.D., co-founder and COO, leads operational and development execution. R1's broader team covers clinical development, alliance management, CMC, quality, clinical operations and finance.

The board also reflects the financing syndicate. Andrew Sinclair represents Abingworth, Tom Musgrave represents DaVita Venture Group, Chong Xu represents F-Prime and Ben Auspitz represents Curie.Bio. That alignment can provide domain expertise and governance support as R1 manages a cross-border clinical program, although clinical data will ultimately carry more weight than syndicate composition.

Samsara partner Abe Bassan framed the investment around the limited innovation available to dialysis patients and AP306's different mechanism. The more important implication is operational: Samsara is joining after the first participant entered Phase 2b and before the study has produced topline results. R1 now has more financing around the stretch of work where trial conduct, dose selection and data quality determine what the mechanism is worth.

What the Financing Can and Cannot Change

The expanded Series A can help R1 keep sites active, supply an investigational medicine, monitor safety, maintain quality systems and prepare for the analysis that will guide regulatory discussions. Those are the ordinary, expensive obligations behind a clinical milestone, and they are precisely where additional runway can protect execution.

The financing cannot settle whether AP306 will reproduce its earlier signal across a larger, geographically distributed study. It cannot establish long-term safety, prove a lower treatment burden in routine care or determine how the drug would fit beside existing phosphate-lowering therapies. Those questions remain attached to the Phase 2b and any later development program.

R1's $80.5M Series A therefore marks a useful handoff. Investors have funded the company through trial initiation, a specialist investor has joined before the readout, and the development team has one clear program to advance. From here, the next chapter will be written in dose arms, laboratory measurements and the quality of the evidence R1 and Alebund can carry into 2027.